SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-088384
Filing Date
2022-03-30
Accepted
2022-03-29 19:01:07
Documents
13
Period of Report
2022-03-29
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d286532d8k.htm   iXBRL 8-K 25551
2 EX-99.1 d286532dex991.htm EX-99.1 43824
  Complete submission text file 0001193125-22-088384.txt   202648

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cmpi-20220329.xsd EX-101.SCH 2881
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cmpi-20220329_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cmpi-20220329_pre.xml EX-101.PRE 11724
7 EXTRACTED XBRL INSTANCE DOCUMENT d286532d8k_htm.xml XML 3480
Mailing Address 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Business Address 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142 978-503-2124
Checkmate Pharmaceuticals, Inc. (Filer) CIK: 0001651431 (see all company filings)

IRS No.: 364813934 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39425 | Film No.: 22782579
SIC: 2836 Biological Products, (No Diagnostic Substances)